1. Report Introduction 2. Celiac Disease (CD) Market Overview at a Glance 2.1. Market Share Distribution of Celiac Disease (CD) in 2016 2.2. Market Share Distribution of Celiac Disease (CD) in 2028 3. Disease Background and Overview: Celiac Disease (CD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Celiac Disease (CD) in 7MM 4.3. Total Prevalent Patient Population of Celiac Disease (CD) in 7MM – By Countries 5. Epidemiology of Celiac Disease (CD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.1.3. Sub-Type Specific cases of the Celiac Disease (CD) * 5.1.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.1.5. Diagnosed Cases of the Celiac Disease (CD) 5.1.6. Treatable Cases of the Celiac Disease (CD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.4.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.4.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.4.5. Diagnosed Cases of the Celiac Disease (CD) 5.4.6. Treatable Cases of the Celiac Disease (CD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.5.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.5.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.5.5. Diagnosed Cases of the Celiac Disease (CD) 5.5.6. Treatable Cases of the Celiac Disease (CD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.6.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.6.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.6.5. Diagnosed Cases of the Celiac Disease (CD) 5.6.6. Treatable Cases of the Celiac Disease (CD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.7.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.7.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.7.5. Diagnosed Cases of the Celiac Disease (CD) 5.7.6. Treatable Cases of the Celiac Disease (CD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.8.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.8.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.8.5. Diagnosed Cases of the Celiac Disease (CD) 5.8.6. Treatable Cases of the Celiac Disease (CD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Celiac Disease (CD) 5.9.3. Sub-Type Specific cases of the Celiac Disease (CD)* 5.9.4. Sex- Specific Cases of the Celiac Disease (CD)* 5.9.5. Diagnosed Cases of the Celiac Disease (CD) 5.9.6. Treatable Cases of the Celiac Disease (CD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Celiac Disease (CD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Celiac Disease (CD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Celiac Disease (CD): 7MM Market Analysis 12.1. 7MM Market Size of Celiac Disease (CD) 12.2. 7MM Percentage Share of drugs marketed for Celiac Disease (CD) 12.3. 7MM Market Sales of Celiac Disease (CD) by Products 13. Celiac Disease (CD): Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Celiac Disease (CD) in United States 13.1.2. Percentage Share of drugs marketed for Celiac Disease (CD) in United States 13.1.3. Market Sales of Celiac Disease (CD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Celiac Disease (CD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Celiac Disease (CD) in Germany 13.2.1.3. Market Sales of Celiac Disease (CD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Celiac Disease (CD) in France 13.2.2.2. Percentage Share of drugs marketed for Celiac Disease (CD) in France 13.2.2.3. Market Sales of Celiac Disease (CD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Celiac Disease (CD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Celiac Disease (CD) in Italy 13.2.3.3. Market Sales of Celiac Disease (CD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Celiac Disease (CD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Celiac Disease (CD) in Spain 13.2.4.3. Market Sales of Celiac Disease (CD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Celiac Disease (CD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Celiac Disease (CD) in United Kingdom 13.2.5.3. Market Sales of Celiac Disease (CD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Celiac Disease (CD) in Japan 13.3.2. Percentage Share of drugs marketed for Celiac Disease (CD) in Japan 13.3.3. Market Sales of Celiac Disease (CD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Celiac Disease (CD) in 7MM Table 2: Total Prevalent/Incident Cases of the Celiac Disease (CD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Celiac Disease (CD) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Celiac Disease (CD) in United States (2016-2028) Table 5: Sex- Specific Cases of the Celiac Disease (CD) in United States (2016-2028) Table 6: Diagnosed Cases of the Celiac Disease (CD) in United States (2016-2028) Table 7: Treatable Cases of the Celiac Disease (CD) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Celiac Disease (CD) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Celiac Disease (CD) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Celiac Disease (CD) in Germany (2016-2028) Table 11: Diagnosed Cases of the Celiac Disease (CD) in Germany (2016-2028) Table 12: Treatable Cases of the Celiac Disease (CD) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Celiac Disease (CD) in France (2016-2028) Table 14: Sub-Type Specific cases of the Celiac Disease (CD) in France (2016-2028) Table 15: Sex- Specific Cases of the Celiac Disease (CD) in France (2016-2028) Table 16: Diagnosed Cases of the Celiac Disease (CD) in France (2016-2028) Table 17: Treatable Cases of the Celiac Disease (CD) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Celiac Disease (CD) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Celiac Disease (CD) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Celiac Disease (CD) in Italy (2016-2028) Table 21: Diagnosed Cases of the Celiac Disease (CD) in Italy (2016-2028) Table 22: Treatable Cases of the Celiac Disease (CD) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Celiac Disease (CD) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Celiac Disease (CD) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Celiac Disease (CD) in Spain (2016-2028) Table 26: Diagnosed Cases of the Celiac Disease (CD) in Spain (2016-2028) Table 27: Treatable Cases of the Celiac Disease (CD) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Celiac Disease (CD) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Celiac Disease (CD) in UK (2016-2028) Table 30: Sex- Specific Cases of the Celiac Disease (CD) in UK (2016-2028) Table 31: Diagnosed Cases of the Celiac Disease (CD) in UK (2016-2028) Table 32: Treatable Cases of the Celiac Disease (CD) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Celiac Disease (CD) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Celiac Disease (CD) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Celiac Disease (CD) in Japan (2016-2028) Table 36: Diagnosed Cases of the Celiac Disease (CD) in Japan (2016-2028) Table 37: Treatable Cases of the Celiac Disease (CD) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 42:7MM- Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 45: United States-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 48: Germany-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 51: France-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 54: Italy-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 57: Spain-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 60:UK-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Table 63: Japan-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Celiac Disease (CD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Celiac Disease (CD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Celiac Disease (CD) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Celiac Disease (CD) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Celiac Disease (CD) in United States (2016-2028) Figure 6: Diagnosed Cases of the Celiac Disease (CD) in United States (2016-2028) Figure 7: Treatable Cases of the Celiac Disease (CD) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Celiac Disease (CD) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Celiac Disease (CD) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Celiac Disease (CD) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Celiac Disease (CD) in Germany (2016-2028) Figure 12: Treatable Cases of the Celiac Disease (CD) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Celiac Disease (CD) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Celiac Disease (CD) in France (2016-2028) Figure 15: Sex- Specific Cases of the Celiac Disease (CD) in France (2016-2028) Figure 16: Diagnosed Cases of the Celiac Disease (CD) in France (2016-2028) Figure 17: Treatable Cases of the Celiac Disease (CD) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Celiac Disease (CD) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Celiac Disease (CD) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Celiac Disease (CD) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Celiac Disease (CD) in Italy (2016-2028) Figure 22: Treatable Cases of the Celiac Disease (CD) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Celiac Disease (CD) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Celiac Disease (CD) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Celiac Disease (CD) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Celiac Disease (CD) in Spain (2016-2028) Figure 27: Treatable Cases of the Celiac Disease (CD) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Celiac Disease (CD) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Celiac Disease (CD) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Celiac Disease (CD) in UK (2016-2028) Figure 31: Diagnosed Cases of the Celiac Disease (CD) in UK (2016-2028) Figure 32: Treatable Cases of the Celiac Disease (CD) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Celiac Disease (CD) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Celiac Disease (CD) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Celiac Disease (CD) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Celiac Disease (CD) in Japan (2016-2028) Figure 37: Treatable Cases of the Celiac Disease (CD) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 42:7MM- Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 45: United States-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 48: Germany-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 51: France-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 54: Italy-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 57: Spain-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 60:UK-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Celiac Disease (CD) in USD MM (2016-2028) Figure 63: Japan-Market Share Celiac Disease (CD) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Celiac Disease (CD) by Therapies in USD MM (2016-2028)